Antifungal Agent Market 2022-2028

Description

List of Tables

Title:Global Antifungal Agent Market Size, Share & Trends Analysis Report By Drug Class (Polyene, Echinocandins, Allylamines, and Azole), By Dosage Form (Powder, Ointment and Drugs), and By Route of Administration (Parenteral, Topical and Oral) Forecast 2022-2028.

The global antifungal agent market is anticipated to grow at a substantial CAGR of 3.1% during the forecast period. Fungal infections have become a major health concern around the globe in recent years. In addition, the occurrence of nosocomial infections is fueling market expansion. Growing cancer occurrences, an increase in hematopoietic stem cell transplantation, and other conditions that impair the immune system are all contributing to the rise of nosocomial infections. As a result of a weakened immune system, fungal infections become more common, fueling market expansion.

On the other hand, the increased availability of generic and pricey medications for the routine treatment of fungal infections is limiting the market growth. Furthermore, the market's expansion is being hampered by the substantial side effects of antifungal medications used to treat fungal infections. Government rules are projected to stifle the market's expansion. For instance, in 2020, the US FDA published guidance on the approval of antibacterial and antifungal drugs. According to the US FDA, antibacterial and antifungal drugs will only be allowed if they are meant to treat a significant life-threatening infection in a small group of patients with unmet needs.

The global antifungal agent market is segmented based on the drug class, dosage form, and routine of administration. Based on the drug class, the market is segmented into polyene, echinocandins, allylamines, and azole. Based on the dosage form, the market is sub-segmented into powder, ointment, and drugs. Based on the routine of administration the market is sub-segmented into parenteral, topical, and oral. The echinocandins category is also driving the growth of the antifungal agent market. The global antifungal medicines market is driven by an increase in the incidence of thrush, also known as oropharyngeal candidiasis, which occurs in the mouth or throat. Echinocandins are caused by the infection, the infection it causes is called candidiasis. Most can be easily treated with over-the-counter or prescription medications which increases the demand for the antifungal market.

Geographically market is segmented into: North America, Europe, Asia Pacific, and the Rest of the World. The market for antifungal medications in North America is one of the largest in the globe. The region's expansion is due to an increase in the occurrence of infectious diseases. The rise in prevalence had heightened the clinical urgency to increase the use of these medications, along with accelerating the development of novel drugs with FDA fast-track authorization. Furthermore, the presence of established pharmaceutical companies that are continually pushing for extensive marketing of their products and expanding their reach is expected to be a crucial factor driving the regional market's expansion.

The major companies serving the global Antifungal agent market include Gilead Sciences, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers &acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in June 2021, Cadila Pharmaceuticals launched Posaconazole, a novel triazole antifungal medicine that is effective against a wide spectrum of invasive fungal illnesses. In addition, the medication has been recommended as a Mucormycosis second-line treatment.

Research Methodology

The market study of the global antifungal agent market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

Financial reports of companies involved in the market.

Whitepapers, research papers, and news blogs.

Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

Global Antifungal Agent Market Research and Analysis by Drug Class.
Global Antifungal Agent Market Research and Analysis by Dosage Form.
Global Antifungal Agent Market Research and Analysis by Route of Administration.

The Report Covers:

Comprehensive research methodology of the global antifungal agent market.
This report also includes a detailed and extensive market overview with key analyst insights.
An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global antifungal agent market.
Insights about market determinants that are stimulating the global antifungal agent market.
Detailed and extensive market segments with the regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.

Product Code: OMR2026788

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Impact of COVID-19 on The Global Antifungal Agent Market
Recovery Scenario of Global Antifungal Agent Market
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. BY Region

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Gilead Sciences, Inc.
- 3.1.1. Overview
- 3.1.2. Financial Analysis
- 3.1.3. SWOT Analysis
- 3.1.4. Recent Developments
3.2. Merck & Co., Inc.
- 3.2.1. Overview
- 3.2.2. Financial Analysis
- 3.2.3. SWOT Analysis
- 3.2.4. Recent Developments
3.3. Novartis AG
- 3.3.1. Overview
- 3.3.2. Financial Analysis
- 3.3.3. SWOT Analysis
- 3.3.4. Recent Developments
3.4. Pfizer Inc.
- 3.4.1. Overview
- 3.4.2. Financial Analysis
- 3.4.3. SWOT Analysis
- 3.4.4. Recent Developments
3.5. Sanofi
- 3.5.1. Overview
- 3.5.2. Financial Analysis
- 3.5.3. SWOT Analysis
- 3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players

4. Market Segmentation

4.1. Global Antifungal Agents Market By Drug Class
- 4.1.1. Polyene
- 4.1.2. Echinocandins
- 4.1.3. Allylamines
- 4.1.4. Azole
4.2. Global Antifungal Agents Market By Dosage Type
- 4.2.1. Powder
- 4.2.2. Ointment
- 4.2.3. Drugs
4.3. Global Antifungal Agents Market By Route of Administration
- 4.3.1. Parenteral
- 4.3.2. Topical
- 4.3.3. Oral

5. Regional Analysis

5.1. North America
- 5.1.1. United States
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. South Korea
- 5.3.5. Rest of Asia-Pacific
5.4. Rest of the World

6. Company Profiles

6.1. Abbott Laboratories, Inc.
6.2. Astellas Pharma Inc.
6.3. Basilea Pharmaceutica Ltd.
6.4. Bayer Healthcare LLC
6.5. Bristol-Myers Squibb Co.
6.6. Cadila Healthcare Ltd.
6.7. Cosmo Pharmaceuticals N.V.
6.8. Dr. Reddy's Laboratories Ltd.
6.9. Enzon Pharmaceuticals, Inc
6.10. Janssen Pharmaceutica NV
6.11. Mayne Pharma Group Ltd.
6.12. SCYNEXIS, Inc.
6.13. Sumitomo Dainippon Pharma Co., Ltd.
6.14. Sun Pharmaceutical Industries Ltd.
6.15. Teva Pharmaceutical Industries Ltd.
6.16. Viatris Inc.